Research Article| Volume 79, ISSUE 2, P163-170, August 2015

Download started.


Treatment with low-dose cytokines reduces oxidative-mediated injury in perilesional keratinocytes from vitiligo skin


      • Primary perilesional keratinocytes (PLK) obtained from vitiligo patients were used.
      • PLK were treated with low-dose 10 fg/ml IL-4, IL-10, bFGF and β-endorphin for 48 h.
      • IL-4, IL-10, bFGF and β-endorphin were prepared by sequential-kinetic-activation.
      • Treatment reduced extra- and intracellular ROS production, increased viability in PLK.
      • Low-dose IL-4, IL-10, bFGF and β-endorphin represent a therapeutic tool for vitiligo.



      Vitiligo is a systemic dermatological disorder characterized by the loss of skin pigmentation due to melanocyte injury or aberrant functioning. Recent data underline its multifactorial etiology with significant involvement of autoimmune and redox alterations. The major role in vitiligo cellular immunity is displayed by augmented Th1 and Th17 and suppressed TREGs and Th2 lymphocyte populations. Our previous studies indicate a marked redox imbalance in perilesional (“PL”, i.e. obtained from visibly unaffected skin surrounding the depigmented area in vitiligo patients) keratinocytes where the massive infiltration of inflammatory cells takes place. No defined therapy exists for vitiligo. Although a number of approaches have been used for the induction of TREGs and Th2 cells, they may be associated with significant off-target effects.


      In order to identify a targeted approach for vitiligo treatment we, first, aimed to investigate the possible source of ROS overproduction in PL keratinocytes. Second, we tested the effect of low-dose selected cytokines, on intra- and extracellular ROS production, cell viability and cell cycle of PL keratinocytes.


      The in vitro study was conducted on primary PL keratinocytes obtained from the skin of vitiligo patients in our previous studies. The activity of NADPH oxidase was measured on intact PL and control keratinocytes, treated or not with cytokines, by luminometric assay. The following cytokines were selected for PL keratinocytes treatment: IL-10 and IL-4 (produced by TREGs and Th2, respectively), basic fibroblasts growth factor (bFGF) and neuropeptide β-endorphin (modulating the cellular resistance to oxidative stress and the immune response, respectively). All cytokines were used at concentration of 10 fg/ml and were prepared by sequential-kinetic-activation (SKA). Intracellular ROS production and cell cycle were analyzed by flow cytometry using H2DCFDA and propidium iodide dyes, respectively. Cell viability was measured by fluorometric resazurin reduction method.


      Our results suggest that NADPH oxidase represents one of the main sources of ROS overproduction by PL keratinocytes. Further, SKA low-dose IL-10, β-endorphin and, particularly, IL-4 and bFGF display a positive effect on redox dyshomeostasis and viability and, in our experimental conditions, don’t affect the cell cycle of PL keratinocytes.


      Our preliminary data suggest that low-dose IL-10, IL-4, β-endorphin and bFGF can be proposed as a new therapeutic tool for vitiligo treatment.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Dermatological Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Alikhan A.
        • Felsten L.M.
        • Daly M.
        • Petronic-Rosic V.
        Vitiligo: a comprehensive overview, Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up.
        J Am Acad Dermatol. 2011; 65: 473-491
        • Tarlé R.G.
        • Nascimento L.M.
        • Mira M.T.
        • Castro C.C.
        Vitiligo—Part 1.
        An Bras Dermatol. 2014; 89: 461-470
        • Laddha N.C.
        • Dwivedi M.
        • Mansuri M.S.
        • Gani A.R.
        • Ansarullah M.
        • Ramachandran A.V.
        • et al.
        Vitiligo: interplay between oxidative stress and immune system.
        Exp Dermatol. 2013; 22: 245-250
        • Dwivedi M.
        • Kemp E.H.
        • Laddha N.C.
        • Mansuri M.S.
        • Weetman A.P.
        • Begum R.
        Regulatory T cells in vitiligo: implications for pathogenesis and therapeutics.
        Autoimmun Rev. 2015; 14: 49-56
        • Sandoval-Cruz M.
        • García-Carrasco M.
        • Sánchez-Porras R.
        • Mendoza-Pinto C.
        • Jiménez-Hernández M.
        • Munguía-Realpozo P.
        • et al.
        Immunopathogenesis of vitiligo.
        Autoimmun Rev. 2011; 10: 762-765
        • Weaver C.T.
        • Harrington L.E.
        • Mangan P.R.
        • Gavrieli M.
        • Murphy K.M.
        Th17: an effector CD4T cell lineage with regulatory T cell ties.
        Immunity. 2006; 24: 677-688
        • Bassiouny D.A.
        • Shaker O.
        Role of interleukin-17 in the pathogenesis of vitiligo.
        Clin Exp Dermatol. 2011; 36: 292-297
        • Prignano F.
        • Pescitelli L.
        • Becatti M.
        • Di Gennaro P.
        • Fiorillo C.
        • Taddei N.
        • et al.
        Ultrastructural and functional alterations of mitochondria in PL vitiligo skin.
        J Dermatol Sci. 2009; 54: 157-167
        • Becatti M.
        • Prignano F.
        • Fiorillo C.
        • Pescitelli L.
        • Nassi P.
        • Lotti T.
        • et al.
        The involvement of Smac/DIABLO, p53, NF-kB, and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: Protective effects of curcumin and capsaicin.
        Antioxid Redox Signal. 2010; 13: 1309-1321
        • Roberti M.L.
        • Ricottini L.
        • Capponi A.
        • Sclauzero E.
        • Vicenti P.
        • Fiorentini E.
        • et al.
        Immunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris.
        J Biol Regul Homeost Agents. 2014; 28: 133-139
        • Radice E.
        • Miranda V.
        • Bellone G.
        Low-doses of sequential-kinetic-activated interferon-γ enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study.
        Int Immunopharmacol. 2014; 19: 66-73
        • D’Amico L.
        • Ruffini E.
        • Ferracini R.
        • Roato I.
        Low dose of IL-12 stimulates T cell response in cultures of PBMCs derived from non small cell lung cancer patients.
        J Cancer Ther. 2012; 3: 337-342
        • Mozzanica N.
        • Villa M.L.
        • Foppa S.
        • Vignati G.
        • Cattaneo A.
        • Diotti R.
        • et al.
        Plasma alpha-melanocyte-stimulating hormone, beta-endorphin, met-enkephalin, and natural killer cell activity in vitiligo.
        J Am Acad Dermatol. 1992; 26: 693-700
        • Burdzińska A.
        • Bartoszuk-Bruzzone U.
        • Godlewski M.M.
        • Orzechowski A.
        Sodium ascorbate and basic fibroblast growth factor protect muscle-derived cells from H2O2-induced oxidative stress.
        Comp Med. 2006; 56: 493-501
        • Zhang H.X.
        • Du G.H.
        • Zhang J.T.
        Assay of mitochondrial functions by resazurin in vitro.
        Acta Pharmacol Sin. 2004; 25: 385-389
        • Takac I.
        • Schröder K.
        • Zhang L.
        • Lardy B.
        • Anilkumar N.
        • Lambeth J.D.
        • et al.
        The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4.
        J Biol Chem. 2011; 286: 13304-13313
        • Kumar Mukhopadhyay A.
        History and evolution of pigmentary disorders in human.
        in: Lahiri Koushik Chatterjee Manas Sarkar Rashmi Pigmentary disorders: a comprehensive compendium. Jaypee Brothers Medical Pub, New Delhi2014: 1-7
        • Lotti T.
        • D’Erme A.M.
        Vitiligo as a systemic disease.
        Clin Dermatol. 2014; 32: 430-434
        • Spritz R.A.
        Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis.
        J Invest Dermatol. 2012; 132: 268-273
        • Spencer J.D.
        • Gibbons N.C.
        • Rokos H.
        • Peters E.M.
        • Wood J.M.
        • Schallreuter K.U.
        Oxidative stress via hydrogen peroxide affects proopiomelanocortin peptides directly in the epidermis of patients with vitiligo.
        J Invest Dermatol. 2007; 127: 411-420
        • Seleit I.
        • Bakry O.A.
        • Abdou A.G.
        • Dawoud N.M.
        Immunohistochemical expression of aberrant Notch-1 signalling in vitiligo: an implication for pathogenesis.
        Ann Diagn Pathol. 2014; 18: 117-124
        • Moretti S.
        • Fabbri P.
        • Baroni G.
        • Berti S.
        • Bani D.
        • Berti E.
        • et al.
        Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis.
        Histol Histopathol. 2009; 24: 849-857
        • Pradhan R.
        • De S.
        • Choudhary N.
        • Mukherjee S.
        • Chatterjee G.
        • Ghosh A.
        • et al.
        Can systemically generated reactive oxygen species help to monitor disease activity in generalized vitiligo?. A pilot study.
        Indian J Dermatol. 2014; 59: 547-551
        • Deo S.S.
        • Bhagat A.R.
        • Shah R.N.
        Study of oxidative stress in peripheral blood of Indian vitiligo patients.
        Indian Dermatol Online J. 2013; 4: 279-282
        • Maresca V.
        • Roccella M.
        • Roccella F.
        • Camera E.
        • Del Porto G.
        • Passi S.
        • et al.
        Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo.
        J Invest Dermatol. 1997; 109: 310-313
        • Colucci R.
        • Böhm M.
        • Moretti S.
        Commentary from the editorial board to vitiligo: interplay between oxidative stress and immune system (Laddha et al.).
        Exp Dermatol. 2013; 22: 397-398
        • Westerhof W.
        • d’Ischia M.
        Vitiligo puzzle: the pieces fall in place.
        Pigment Cell Res. 2007; 20: 345-359
        • Speeckaert R.
        • Speeckaert M.M.
        • van Geel N.
        Why treatments do(n’t) work in vitiligo: an autoinflammatory perspective.
        Autoimmun Rev. 2015; 14: 332-340
        • Schallreuter K.U.
        • Moore J.
        • Wood J.M.
        • Beazley W.D.
        • Gaze D.C.
        • Tobin D.J.
        • et al.
        In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase.
        J Investig Dermatol Symp Proc. 1999; 4: 91-96
        • Schallreuter K.U.
        • Salem M.A.
        • Gibbons N.C.
        • Martinez A.
        • Slominski R.
        • Lüdemann J.
        • et al.
        Blunted epidermal l-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, Part 1: Epidermal H2O2/ONOO(−)-mediated stress abrogates tryptophan hydroxylase and dopa decarboxylase activities, leading to low serotonin and melatonin levels.
        FASEB J. 2012; 26: 2457-2470
        • Schallreuter K.U.
        • Salem M.A.
        • Gibbons N.C.
        • Maitland D.J.
        • Marsch E.
        • Elwary S.M.
        • et al.
        Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, Part 2: Epidermal H2O2/ONOO(−)-mediated stress in vitiligo hampers indoleamine 2,3-dioxygenase and aryl hydrocarbon receptor-mediated immune response signaling.
        FASEB J. 2012; 26: 2471-2485
        • Chamulitrat W.
        • Stremmel W.
        • Kawahara T.
        • Rokutan K.
        • Fujii H.
        • Wingler K.
        • et al.
        A constitutive NADPH oxidase-like system containing gp91phox homologs in human keratinocytes.
        J Invest Dermatol. 2004; 122: 1000-1009
        • Krieger-Brauer H.I.
        • Kather H.
        Antagonistic effects of different members of the fibroblast and platelet-derived growth factor families on adipose conversion and NADPH-dependent H2O2 generation in 3T3 L1-cells.
        Biochem J. 1995; 307: 549-556
        • Caixia T1
        • Daming Z.
        • Xiran L.
        Levels of beta-endorphin in the plasma and skin tissue fluids of patients with vitiligo.
        J Dermatol Sci. 2001; 26: 62-66
        • Marinaro M.
        • Boyaka P.N.
        • Finkelman F.D.
        • Kiyono H.
        • Jackson R.J.
        • Jirillo E.
        • et al.
        Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses.
        J Exp Med. 1997; 185: 415-427
        • Cummins J.M.
        • Krakowka G.S.
        • Thompson C.G.
        Systemic effect of interferons after oral administration in animals and humans.
        Am J Vet Res. 2005; 66: 164-176
        • Brod S.A.
        • Khan M.
        Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis.
        J Autoimmun. 1996; 9: 11-20